Volume Alert - GILD 106.54 Gilead Sciences $GILD Hit a high

New Post Public Reply Private Reply Replies (0) Message Board

Nov 12, 2014 at 11:30 AM

Volume Alert - GILD 106.54 Gilead Sciences $GILD Hit a high today of 107.81 Closing the day 10:30 at 106.54 -1.47 -1.36% With a day low of 105.70 and a total volume of 3,398,247.

GILD Recent Posts: http://investorshangout.com/Gilead-Sciences-Inc-GILD-54232/

GILD Gilead Sciences Recent Headline News

Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio
IAEResearch - at Seeking Alpha - 12 mins ago

GILD: 106.85 (-1.16)

Early Glance: Biotechnology companies
AP - 24 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.01 (-0.84)

Biotech Stock Roundup: Gilead, AbbVie Score at Liver Meeting, Dendreon Files for Bankruptcy - Analyst Blog
Arpita Dutt - Zacks Investment Research - 2 hrs 41 mins ago
Companies like AbbVie (ABBV), Gilead (GILD) and Achillion (ACHN) had a strong presence at the annual Liver Meeting.
VRTX: 116.01 (-1.48), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), DNDN: 0.16 (+0.01), AMGN: 161.31 (-1.11), ABBV: 63.84 (-0.01), REGN: 399.27 (+0.91)

Earnings Forecast Recap for Alibaba, Apple, Zynga, Gilead Sciences, Dendreon, and Juniper
PR Newswire - 2 hrs 44 mins ago
EarningForecast.com has issued six earnings forecast research reports with special focus on financial performance of the following stocks: Alibaba (NYSE:BABA), Apple (NASDAQ:AAPL), Zynga (NASDAQ:ZNGA), Gilead Sciences (NASDAQ:GILD), Dendreon (NASDAQ

NDN), and Juniper (NYSE:JNPR).
GILD: 106.85 (-1.16), DNDN: 0.16 (+0.01), ZNGA: 2.82 (+0.07), AAPL: 110.62 (+0.92), JNPR: 20.54 (+0.26), BABA: 117.35 (+2.81)

This Tiny Biotech Is Piggybacking on Gilead Sciences, Inc.'s Success
Todd Campbell, The Motley Fool - Motley Fool - 2 hrs 46 mins ago
Source: Gilead Sciences. Developing drugs that help established blockbusters work better is a major trend in biotechnology. It's a lower-stakes game because drug developers only need to show that their products can improve upon existing therapies,...
GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 77.10 (-0.56), SJR: 25.86 (-0.22), PRGO: 154.26 (-1.18), XYL: 37.33 (-0.02), CHRW: 72.10 (+0.35), MDLZ: 37.67 (-0.10), MKC: 72.79 (-0.43), MDU: 25.41 (-0.30), SYY: 38.81 (+0.29), PDCO: 44.63 (+0.36), PNR: 67.98 (-0.14), TRI: 38.10 (+0.18), UPS: 107.98 (-0.78), PEP: 96.91 (+0.21), AGN: 197.22 (+1.88), MSI: 63.64 (+0.09), NOV: 73.29 (+0.19), NWN: 46.87 (-0.62), EGN: 68.07 (-0.71), EBAY: 53.89 (-0.30), QCOM: 70.27 (+0.63), AMAT: 22.38 (-0.16), ACN: 83.74 (-0.20), AAPL: 110.62 (+0.92), MA: 84.14 (-0.45), SCHW: 28.73 (-0.12), STR: 23.78 (-0.51), SE: 39.03 (-0.30), GAS: 52.02 (-1.25), IRM: 37.99 (+0.16), WM: 49.35 (-0.01), CMP: 88.71 (+0.69), VRSK: 62.85 (-0.16), GILD: 106.85 (-1.16), EXPD: 44.03 (-0.23), TFX: 113.85 (-0.48), CVS: 89.19 (-0.57), PG: 89.63 (-0.04), PX: 126.08 (-0.62), NVS: 92.66 (-0.11)

Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.22 (+1.88), GILD: 106.85 (-1.16), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)

Gilead up on Harvoni results
at Investor's Business Daily - Tue Nov 11, 5:30PM CST
The drugmaker said that its new Harvoni drug achieved cure rates of 96%-97% in a study of patients who had cirrhosis and had failed to respond to prior treatments. Harvoni is Gilead's (GILD) hepatitis C pill that combines its blockbuster Sovaldi drug...
GILD: 106.85 (-1.16)

Final Glance: Biotechnology companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 106.85 (-1.16), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)

Achillion Jumps on Encouraging Data on its HCV Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:10PM CST
Shares of Achillion Pharmaceuticals (ACHN) soared over 27% after the company reported encouraging interim results on ACH-3102.
JNJ: 108.56 (-0.35), GILD: 106.85 (-1.16), ACHN: 13.16 (+0.68), AMAG: 34.74 (-0.14)

Merck down on hep C data
at Investor's Business Daily - Mon Nov 10, 6:00PM CST
Shares of big pharma Merck (MRK) fell hard after the latest data from its hepatitis C combination drug trial disappointed Wall Street. The drugmaker on Sun. reported interim data for its C-Swift trial, showing just 39% of patients were free of the...
GILD: 106.85 (-1.16), MRK: 59.20 (-0.17)

Gilead: Another Competitor Bites The Dust
Bret Jensen - at Seeking Alpha - Tue Nov 11, 1:10PM CST

GILD: 106.85 (-1.16)

Midday Glance: Biotechnology companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.84 (-1.17), AMGN: 161.31 (-1.11), CELG: 107.02 (-0.83)

Conatus Pharmaceuticals (CNAT): Will Loss Narrow in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 12:50PM CST
Conatus Pharmaceuticals Inc, Inc. (CNAT) is expected to report third-quarter 2014 results on Nov 12.
MNK: 93.22 (-0.49), GILD: 106.86 (-1.15), CNAT: 6.87 (-0.19), ICPT: 155.82 (-17.31)

Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), MRK: 59.20 (-0.17), ABBV: 63.84 (-0.01), BMY: 58.55 (-0.17)

Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST

JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)

Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST

VRTX: 116.01 (-1.48), GILD: 106.86 (-1.15), MRK: 59.20 (-0.17), DNDN: 0.16 (+0.01), AZN: 74.13 (-0.07), TEVA: 58.20 (+0.01), ABBV: 63.85 (unch), GSK: 45.65 (-0.31), BMY: 58.55 (-0.17), NVS: 92.66 (-0.11)

Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 377.95 (-4.60), YHOO: 49.96 (+0.91), AMZN: 309.71 (-2.30), BIIB: 319.95 (-4.64), VRTX: 116.01 (-1.48), FEYE: 32.64 (-0.21), LNKD: 229.43 (-1.57), EBAY: 53.89 (-0.30), GILD: 106.86 (-1.15), AMGN: 161.31 (-1.11), ABBV: 63.85 (unch), REGN: 399.27 (+0.91), CELG: 107.02 (-0.83)

AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST

JNJ: 108.56 (-0.35), GILD: 106.86 (-1.15), ACHN: 13.16 (+0.68), CNAT: 6.87 (-0.19), MRK: 59.20 (-0.17), RGLS: 20.03 (-0.44), ABBV: 63.85 (unch), BMY: 58.55 (-0.17), ENTA: 43.16 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hyliion Faces Legal Drama Over Securities Violations

A Stock Tango Entangled in Legal Webs Ah, Hyliion Holdings Corp. (NYSE American: HYLN) finds itself in the legal crosshairs this time around. On October 20, 2026, DJS Law Group sounded the alarm, reminding investors that there’s a class action lawsuit hanging over Hyliion's head like a gray cloud over a picnic. Allegations of securities law violations are the game of...

Arbor Scientia Snags Second Consecutive BASA Win

Picture a small business breaking into the spotlight, grabbing the industry’s attention two years in a row: That’s the story of Arbor Scientia Group (ASG), bagging its second consecutive BASA Award. Celebrated within the Education and Training category, this global medical education and communications agency—not just a regular name in the field—has made measurable...

PetroCal Drives Dual Mandate for Orlando Car Wash

PetroCal's Double Play in the Real Estate Game When you've been in this game as long as I have, you learn to keep an eye on players who can juggle multiple roles. And that's exactly what PetroCal Associates has pulled off with the Tommy's Express Car Wash project in Orlando. This isn't just another carwash setup, folks. We're talking about integrating into Unicorp...

Chemours Faces Heat: 18.63% Stock Drop Jolts Investors

Investors Rattled by Chemours' Stark Drop One moment, you're cruising along with the market, and the next, news hits like a brick. That’s what investors in The Chemours Company (NYSE: CC) faced when shares nosedived 18.63% after some unsettling revelations. Let's peel back the layers and see what's got everyone in a tizzy. What's Behind the Lawsuit? Securities lawsuits...

iLAB Network Fuels Next-Gen Tech Startups with Innovation

Igniting Innovation: 2150's New iLAB Network Here's the skinny on what's cookin' at the 2150 Center for Innovation, Commercialization & Growth. They've bagged another cohort for their iLAB network, and they’re laying the groundwork for the next wave of tech solutions that could shake things up across industries. Fresh Collaborations and Technological Foci Essentially,...

Ashford Hospitality Trust: Fee Waiver and Share Buyback

Strategic Moves in a Challenging Market When it rains, it pours. Ashford Hospitality Trust (NYSE: AHT), the real estate investment trust that's got its fingers in the hotel industry pie, is shaking things up with some bold maneuvers. The company just dropped a bombshell: it's waiving a $17 million advisory fee, buying back shares, and terminating its at-the-market (ATM)...

First New Vegas Strip Intersection in 60 Years Planned

Change Is Coming to the Las Vegas Strip Las Vegas is about to shake things up in a way not seen for six long decades. Yep, they're breaking ground on a brand new intersection on the Strip! You heard me right—Russell Road and Las Vegas Boulevard are getting some fresh asphalt, thanks to the backing of State Senator Fabian Doñate and Assemblymember Cecelia González....

AMTD IDEA Group: Expanding Its Global Reach

AMTD IDEA's Expansive Global Footprint While the rest of the market whirls, AMTD IDEA Group (NYSE: AMTD) is steadying itself with a comprehensive expansion that, quite frankly, demands a second look. Between weaving global media threads and dipping their toes into every alluring venture space, they've formed a tapestry not many could replicate. With facilities stretching...

Shadeform's Spot: Monetizing Idle GPU Resources

Shadeform's Spot Aims To Cut GPU Waste Imagine letting money burn while your GPUs sit in idle mode. That's the reality for many in the cloud computing sector, and Shadeform looks ready to tackle this inefficiency head-on. The launch of Spot, by the GPU Cloud Marketplace Shadeform, offers a novel way to make sure every floating gigaflop translates into some form of...

Lawsuit Filed for Unfair ODP Acquisition Price

Is ODP Getting a Raw Deal? Grab a cup of joe, because this is one of those sticky situations where the stakes are high, and the details are grimmer than last week's sales report. On August 19, 2026, Monteverde & Associates PC filed a lawsuit targeting the acquisition of The ODP Corporation by Atlas Holdings LLC, claiming the buyout price wasn't just low—it was roaringly...